Cargando…

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors

The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA. In cancer, many of the proteins that regulate these modifications can be altered in both function and expression. One example of this is the family of histone deacetylas...

Descripción completa

Detalles Bibliográficos
Autores principales: Federico, Mario, Bagella, Luigi
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004414/
https://www.ncbi.nlm.nih.gov/pubmed/21188171
http://dx.doi.org/10.1155/2011/475641
_version_ 1782193979041775616
author Federico, Mario
Bagella, Luigi
author_facet Federico, Mario
Bagella, Luigi
author_sort Federico, Mario
collection PubMed
description The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA. In cancer, many of the proteins that regulate these modifications can be altered in both function and expression. One example of this is the family of histone deacetylases (HDACs), which as their name implies remove acetyl groups from the histone proteins, allowing for more condensed nucleosomal structure. HDACs have increased expression in cancer and are also believed to promote carcinogenesis through the acetylation and interaction with key transcriptional regulators. Given this, small molecule histone deacetylases inhibitors have been identified and developed, which not only inhibit HDACs, but can also lead to growth arrest, differentiation, and/or apoptosis in tumors both in vitro and in vivo. Here, we will discuss some of the recent developments in clinical trials utilizing HDACs inhibitors for the treatment of both hematological malignancies as well as solid tumors.
format Text
id pubmed-3004414
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30044142010-12-23 Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors Federico, Mario Bagella, Luigi J Biomed Biotechnol Review Article The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA. In cancer, many of the proteins that regulate these modifications can be altered in both function and expression. One example of this is the family of histone deacetylases (HDACs), which as their name implies remove acetyl groups from the histone proteins, allowing for more condensed nucleosomal structure. HDACs have increased expression in cancer and are also believed to promote carcinogenesis through the acetylation and interaction with key transcriptional regulators. Given this, small molecule histone deacetylases inhibitors have been identified and developed, which not only inhibit HDACs, but can also lead to growth arrest, differentiation, and/or apoptosis in tumors both in vitro and in vivo. Here, we will discuss some of the recent developments in clinical trials utilizing HDACs inhibitors for the treatment of both hematological malignancies as well as solid tumors. Hindawi Publishing Corporation 2011 2010-12-06 /pmc/articles/PMC3004414/ /pubmed/21188171 http://dx.doi.org/10.1155/2011/475641 Text en Copyright © 2011 M. Federico and L. Bagella. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Federico, Mario
Bagella, Luigi
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
title Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
title_full Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
title_fullStr Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
title_full_unstemmed Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
title_short Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
title_sort histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004414/
https://www.ncbi.nlm.nih.gov/pubmed/21188171
http://dx.doi.org/10.1155/2011/475641
work_keys_str_mv AT federicomario histonedeacetylaseinhibitorsinthetreatmentofhematologicalmalignanciesandsolidtumors
AT bagellaluigi histonedeacetylaseinhibitorsinthetreatmentofhematologicalmalignanciesandsolidtumors